American Association for Cancer Research

SHERPA: Unknown

People

  1. Kris
    Kris
  2. Rudin
    Rudin
  3. Ladanyi
    Ladanyi
  4. Riely
    Riely
  5. Drilon
    Drilon
  6. Arcila
    Arcila
  7. De Stanchina
    De Stanchina
  8. Berger
    Berger
  9. Rekhtman
    Rekhtman
  10. Offin
    Offin

Groups

  1. Department of Medicine (285)
  2. Solid Tumor Oncology Division (285)
  3. Thoracic Oncology (285)
  4. GSK Faculty (156)
  5. Department of Pathology and Laboratory Medicine (96)
  6. Human Oncology and Pathogenesis Program (92)
  7. Center for Molecular Imaging and Biotechnology (CMIB) (91)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (83)
  9. Sloan Kettering Institute Postdocs (72)
  10. Tow Center for Developmental Oncology (TCDO) (69)
Search Within
  1. "Thoracic Oncology"
Formats
  1. Journal Article (151)
  2. Meeting Abstract (126)
  3. Editorial (4)
  4. Review (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (285)
  2. Solid Tumor Oncology Division (285)
  3. Thoracic Oncology (285)
  4. GSK Faculty (156)
  5. Department of Pathology and Laboratory Medicine (96)
  6. Human Oncology and Pathogenesis Program (92)

More Groups

People
  1. Mark Kris (76)
  2. Charles Rudin (65)
  3. Marc Ladanyi (63)
  4. Gregory Riely (60)
  5. Alexander Drilon (54)
  6. Matthew Hellmann (43)

More People

Years
  1. 2025 (7)
  2. 2024 (4)
  3. 2023 (11)
  4. 2022 (34)
  5. 2021 (36)
  6. 2020 (31)

More Years

Publications
  1. Clinical Cancer Research (156)
  2. Cancer Research (129)

Results (285)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RIT1 drives oncogenic transformation and is an actionable target in lung adenocarcinoma
    Journal Article

    Mozzarelli, A. M.; Cuevas-Navarro, A.; Shuldiner, E. G.; Vega, M.; Chatila, W. K.; Xu, J.; Walch, H. S.; Niu, Y. Z.; Petrov, D. A.; Schultz, N.; more...
    Cancer Research (2025)

    Fulltext@MSK | Save
  • Safety and tolerability of lete-cel in NSCLC—Reply
    Correspondence

    Altan, M.; Lopes, G.; Hiltermann, T. J. N.; Govindan, R.; Villaruz, L. C.; Calvo, E.; Edelman, M. J.; Furqan, M.; Neal, J.; Felip, E.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • The lung cancer autochthonous model gene expression database enables cross-study comparisons of the transcriptomic landscapes across mouse models
    Journal Article

    Cai, L.; Wu, F.; Zhou, Q.; Gao, Y.; Yao, B.; DeBerardinis, R. J.; Acquaah-Mensah, G. K.; Aidinis, V.; Beane, J. E.; Biswal, S.; more...
    Cancer Research (2025)

    Fulltext@MSK | Save
  • Can longitudinal biomarkers guide treatment decisions? Time will tell
    Editorial

    Jeng, M. Y.; Schoenfeld, A. J.
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of central nervous system tumors harboring NTRK gene fusions
    Journal Article

    Lamoureux, A. A.; Fisher, M. J.; Lemelle, L.; Pfaff, E.; Amir-Yazdani, P.; Kramm, C.; De Wilde, B.; Kazanowska, B.; Hutter, C.; Pfister, S. M.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Safety and tolerability of letetresgene autoleucel (GSK3377794): Pilot studies in patients with advanced non–small cell lung cancer
    Journal Article

    Altan, M.; Lopes, G.; Hiltermann, T. N. J.; Govindan, R.; Villaruz, L. C.; Calvo, E.; Edelman, M. J.; Furqan, M.; Neal, J.; Felip, E.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Divergent clinical and immunologic outcomes based on STK11 Co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade
    Journal Article

    Rosner, S.; Connor, S.; Sanber, K.; Zahurak, M.; Zhang, T.; Gurumurthy, I.; Zeng, Z.; Presson, B.; Singh, D.; Rayes, R.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of BRAF fusions identifies actionable targets
    Journal Article

    Chen, M. F.; Yang, S. R.; Tao, J. J.; Desilets, A.; Diamond, E. L.; Wilhelm, C.; Rosen, E.; Gong, Y.; Mullaney, K.; Torrisi, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer
    Journal Article

    Choudhury, N. J.; Lai, W. V.; Makhnin, A.; Heller, G.; Eng, J.; Li, B.; Preeshagul, I.; Santini, F. C.; Offin, M.; Ng, K.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Diffuse pleural mesotheliomas with genomic near-haploidization: A newly recognized subset with distinct clinical, histologic, and molecular features
    Journal Article

    Yang, S. R.; Jayakumaran, G.; Benhamida, J.; Febres-Aldana, C. A.; Fanaroff, R.; Chang, J.; Gedvilaite, E.; Villafania, L. B.; Sauter, J. L.; Offin, M.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: